Charles H. Weaver

2.8k total citations · 1 hit paper
29 papers, 1.4k citations indexed

About

Charles H. Weaver is a scholar working on Oncology, Hematology and Cancer Research. According to data from OpenAlex, Charles H. Weaver has authored 29 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Hematology and 8 papers in Cancer Research. Recurrent topics in Charles H. Weaver's work include Hematopoietic Stem Cell Transplantation (16 papers), Neutropenia and Cancer Infections (11 papers) and Cancer Treatment and Pharmacology (5 papers). Charles H. Weaver is often cited by papers focused on Hematopoietic Stem Cell Transplantation (16 papers), Neutropenia and Cancer Infections (11 papers) and Cancer Treatment and Pharmacology (5 papers). Charles H. Weaver collaborates with scholars based in United States and South Africa. Charles H. Weaver's co-authors include K Lilleby, Jack W. Singer, Ted Gooley, Jan‐Stephan Sanders, F R Appelbaum, Scott D. Rowley, Taner Demirer, K Schiffman, Rainer Storb and Robert Birch and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Haematology.

In The Last Decade

Charles H. Weaver

29 papers receiving 1.3k citations

Hit Papers

Factors that influence collection and engraftment of auto... 1995 2026 2005 2015 1995 100 200 300 400 500

Peers

Charles H. Weaver
Esteban Abella United States
GE Sale United States
S Milan United Kingdom
R A Clift United States
NC Gorin France
Appelbaum Fr United States
Karin Kolbe Germany
N. Schwella Germany
Esteban Abella United States
Charles H. Weaver
Citations per year, relative to Charles H. Weaver Charles H. Weaver (= 1×) peers Esteban Abella

Countries citing papers authored by Charles H. Weaver

Since Specialization
Citations

This map shows the geographic impact of Charles H. Weaver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles H. Weaver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles H. Weaver more than expected).

Fields of papers citing papers by Charles H. Weaver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles H. Weaver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles H. Weaver. The network helps show where Charles H. Weaver may publish in the future.

Co-authorship network of co-authors of Charles H. Weaver

This figure shows the co-authorship network connecting the top 25 collaborators of Charles H. Weaver. A scholar is included among the top collaborators of Charles H. Weaver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles H. Weaver. Charles H. Weaver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Curtis, Lesley H., Bradley G. Hammill, Jatinder Kaur Dhillon, et al.. (2007). The medicare modernization act and reimbursement for outpatient chemotherapy. Cancer. 110(10). 2304–2312. 10 indexed citations
2.
Linker, Charles, Paolo Anderlini, Roger H. Herzig, et al.. (2003). Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biology of Blood and Marrow Transplantation. 9(6). 405–413. 24 indexed citations
3.
Burgess, J, Bonnie Mills, Virginia H. Mansour, et al.. (2001). Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34+ cells. Cytotherapy. 3(4). 285–294. 5 indexed citations
4.
Weaver, Charles H., L. Schwartzberg, B Zhen, et al.. (1999). Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: a randomized trial of 3 vs 4 g/m2 of CY. Bone Marrow Transplantation. 23(5). 421–425. 9 indexed citations
5.
Schwartzberg, Lee S., Robert Birch, Kurt W. Tauer, et al.. (1999). Adjuvant Dose-Intense Chemotherapy With Peripheral Blood Stem Cell Support in Stage II-III Breast Cancer With Five to Nine Involved Axillary Lymph Nodes. American Journal of Clinical Oncology. 22(2). 136–142. 3 indexed citations
6.
Schulman, Kevin A., et al.. (1999). Effect of CD34+ Cell Dose on Resource Utilization in Patients After High-Dose Chemotherapy With Peripheral-Blood Stem-Cell Support. Journal of Clinical Oncology. 17(4). 1227–1227. 65 indexed citations
7.
Schwartzberg, Lee S., Charles H. Weaver, Robert Birch, et al.. (1998). A Randomized Trial of Two Doses of Cyclophosphamide with Etoposide and G-CSF for Mobilization of Peripheral Blood Stem Cells in 318 Patients with Stage II-III Breast Cancer. Journal of Hematotherapy. 7(2). 141–150. 10 indexed citations
8.
Weaver, Charles H., Kurt W. Tauer, B Zhen, et al.. (1998). Second Attempts at Mobilization of Peripheral Blood Stem Cells in Patients with Initial Low CD34+ Cell Yields. Journal of Hematotherapy. 7(3). 241–249. 51 indexed citations
9.
Weaver, Charles H., Robert Birch, FA Greco, et al.. (1998). Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. British Journal of Haematology. 100(2). 338–347. 70 indexed citations
10.
Gaskin, Darrell J., et al.. (1998). Treatment Choices by Seriously III Patients. Medical Decision Making. 18(1). 84–94. 23 indexed citations
11.
Schwartzberg, Lee S., Robert Samuel Birch, William H. West, et al.. (1998). Sequential Treatment Including High-Dose Chemotherapy With Peripheral Blood Stem Cell Support in Patients With High-Risk Stage II-III Breast Cancer. American Journal of Clinical Oncology. 21(5). 523–531. 8 indexed citations
13.
Buckner, C. Dean, Robert Birch, & Charles H. Weaver. (1998). The Rationale for not Routinely Purging Autologous Blood Stem Cell Grafts. Hematology. 3(2). 107–117. 2 indexed citations
14.
Weaver, Charles H., Lee S. Schwartzberg, Robert Birch, et al.. (1997). Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte‐colony‐ stimulating factor: an analysis of 497 patients. Transfusion. 37(9). 896–903. 49 indexed citations
15.
Demirer, Taner, Charles H. Weaver, CD Buckner, et al.. (1995). High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy.. Journal of Clinical Oncology. 13(3). 596–602. 71 indexed citations
16.
Weaver, Charles H., Robert Birch, Lee S. Schwartzberg, & William H. West. (1995). High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast Cancer. Cancer treatment and research. 76. 59–85. 7 indexed citations
17.
Singer, Jack W., F R Appelbaum, Scott D. Rowley, et al.. (1995). Factors that influence collection and engraftment of autologous peripheral-blood stem cells.. Journal of Clinical Oncology. 13(10). 2547–2555. 529 indexed citations breakdown →
19.
20.
Weaver, Charles H., et al.. (1988). Bacterial vaginosis.. PubMed. 27(2). 207–15. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026